A Phase II, Neoadjuvant, Randomized, Multicenter Study of Imprime PGG Plus Pembrolizumab in Subjects With Stage III, Resectable Melanoma
Latest Information Update: 09 Nov 2021
At a glance
- Drugs Odetiglucan (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Therapeutic Use
- Sponsors HiberCell
- 29 Oct 2021 Status changed from recruiting to withdrawn prior to enrolment.
- 13 Aug 2021 New trial record